Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGONIVOCTx: regorafenib + nivolumab + chemotherapy in advanced gastric/GEJ/esophageal adenocarcinoma
jRCT2031220089Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of regorafenib and nivolumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 cohorts), sponsored by Bayer. Primary endpoints: Dose-limiting toxicities incidence (Phase Ib) and Objective response rate (Phase II). Started Jun 2022; status: active, not recruiting.
02
Drugs
regorafenibnivolumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031220089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220089.